The global primary cells market is projected to reach USD 2.8 billion by 2028 from USD 1.7 billion in 2023, at a CAGR of 10.5% during the forecast period. The growth of this market can be attributed to factors such as the is the growing advantages of primary human cells over cell lines, growth in pharmaceutical & biotechnology industries, increasing demand for monoclonal antibodies, government investments for cell-based research, and increasing cancer research.

Request To Download Sample of This Strategic Report @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=32854960

Primary cells refer to cells taken directly from living tissues of animals or humans and are then processed to establish them for use in appropriate cell therapies. Primary cells are widely used in various applications, including 3D cell culture, virology, cancer research, stem cell therapy, and tissue replacement.

This study involved four major activities in estimating the current size of the primary cells market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research.

North America is the largest regional market for primary cells market

The primary cells market is segmented into four major regions, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America accounted for the largest share in the primary cells market. The growth in the North American primary cells market can be attributed to increasing funding for cancer research, growing life science research sector, expansion of the healthcare sector, and the high adoption of stem cell therapy & cell immunotherapies for the treatment of cancer and chronic diseases.

Key Market Players

 Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Lonza (Switzerland), Cell Biologics, Inc. (US), PromoCell GmbH (Germany), HemaCare Corporation (US), ZenBio, Inc. (US), STEMCELL Technologies, Inc. (Canada), Corning Incorporated (US), AllCells (US), American Type Culture Collection (US), Axol Bioscience Ltd. (UK), iXCells Biotechnologies (US), Neuromics (US), StemExpress (US), BioIVT (US), ScienCell Research Laboratories, Inc. (US), PPA Research Group, Inc. (US), Creative Bioarray (US), BPS Bioscience, Inc. (US), Epithelix Sàrl (Switzerland), ReachBio LLC (US), AcceGen (US), Sekisui XenoTech, LLC (US), and Biopredic International (France).

For a detailed look at our Table of Contents @  https://www.marketsandmarkets.com/Market-Reports/primary-cells-market-32854960.html

This report categorizes the primary cells market into the following segments and subsegments:

By Origin

  • Human Primary Cells
  • Animal Primary Cells

By Type

  • Hematopoietic Cells
  • Dermatocytes
  • Gastrointestinal Cells
  • Hepatocytes
  • Lung Cells
  • Renal Cells
  • Heart Cells
  • Musculoskeletal Cells
  • Other Primary Cells

By End User

  • Life Science Research Companies
  • Research Institutes

By Region

  • North America
  • Europe
  • Asia Pacific

Recent Developments

  • BioIVT (US) introduced high-purity Kupffer cells to its portfolio of human primary hepatic cells to support liver disease drug discovery and development.
  •  Charles River Laboratories acquired HemaCare Corporation. This acquisition will aid in expanding Charles River’s scientific capabilities in the high-growth cell therapy sector.
  • Sekisui XenoTech, LLC. (US) added monkey and rodent hepatocytes to its patented CryostaX product line.

Buy-Now this Premium Report @ https://www.marketsandmarkets.com/Purchase/purchase_reportNew.asp?id=32854960

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Aashish Mehra

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA : 1-888-600-6441

sales@marketsandmarkets.com